tailieunhanh - The relationship between blood-based tumor mutation burden level and efficacy of PD-1/PD-L1 inhibitors in advanced nonsmall cell lung cancer: A systematic review and meta-analysis

The predictive role of blood-based tumor mutation burden (bTMB) for selecting advanced nonsmall cell lung cancer (NSCLC) patients who might benefit from immune checkpoint inhibitors (ICIs) is still under debate. |

TÀI LIỆU LIÊN QUAN
TỪ KHÓA LIÊN QUAN